These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26394624)

  • 21. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.
    Wang ZY; Zeng FQ; Zhu ZH; Jiang GS; Lv L; Wan F; Dong R; Xiao XY; Xing SA
    Urol Oncol; 2012; 30(2):167-76. PubMed ID: 20864366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
    Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
    Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status.
    Fondrevelle ME; Kantelip B; Reiter RE; Chopin DK; Thiery JP; Monnien F; Bittard H; Wallerand H
    Urol Oncol; 2009; 27(3):268-76. PubMed ID: 18440840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of classic cadherins type I in urothelial neoplastic progression.
    Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
    Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
    Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
    Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
    Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S
    BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
    Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
    Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.
    Hensley PJ; Zetter D; Horbinski CM; Strup SE; Kyprianou N
    Hum Pathol; 2016 Nov; 57():68-77. PubMed ID: 27402302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
    Fristrup N; Ulhøi BP; Birkenkamp-Demtröder K; Mansilla F; Sanchez-Carbayo M; Segersten U; Malmström PU; Hartmann A; Palou J; Alvarez-Múgica M; Zieger K; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2012 May; 180(5):1824-34. PubMed ID: 22449953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
    Yin W; Chen N; Zhang Y; Zeng H; Chen X; He Y; Wang X; Zhou Q
    Mod Pathol; 2006 Nov; 19(11):1487-97. PubMed ID: 16892011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Establishment of the prognostic evaluation system of T1G3 bladder urothelial cancer].
    Li XD; Sun G; Liu XQ
    Zhonghua Wai Ke Za Zhi; 2013 Aug; 51(8):741-5. PubMed ID: 24252684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
    Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
    Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
    Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
    Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of epithelial-Mesenchymal transition related markers in Plasmacytoid Urothelial carcinoma of the urinary bladder.
    Nomura S; Suzuki Y; Akatsuka J; Endo Y; Shimizu A; Hamasaki T; Kimura G; Kondo Y
    BMC Urol; 2020 Jun; 20(1):72. PubMed ID: 32571273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
    Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
    Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.